Every Form 4 that Enveric Biosciences, Inc. (ENVB) has filed with the SEC in the last 12 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A Form 4 covers the transactions officers, directors and large holders report, so if you follow ENVB and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full ENVB filings page.
Coveney Kevin Michael reported acquisition or exercise transactions in this Form 4 filing.
Enveric Biosciences, Inc. reported that Chief Financial Officer Kevin Michael Coveney received a grant of 133,333 restricted stock units under the company’s 2020 Long-Term Incentive Plan. These RSUs are a form of equity compensation and were granted at no cash cost per unit.
For each vested RSU, Coveney will receive one share of common stock, bringing his total reported direct holdings to 180,746 shares after the grant. One-fourth of the RSUs will vest on the one-year anniversary of the grant date, then one‑thirty‑sixth will vest each month, with any remaining RSUs vesting on the fourth anniversary, all conditioned on continued employment.
Enveric Biosciences, Inc. CEO Joseph Edward Tucker received a grant of 201,124 restricted stock units of common stock under the company’s 2020 Long-Term Incentive Plan. These RSUs have no cash exercise price; one share of common stock will be issued for each vested unit. One-fourth of the RSUs will vest on the one-year anniversary of the grant date, with an additional one‑thirty‑sixth vesting each month thereafter, and any remaining RSUs vesting on the fourth anniversary, subject to continued employment. Following this award, Tucker directly holds 271,479 shares of common stock.
PASQUALONE FRANK reported acquisition or exercise transactions in this Form 4 filing.
Enveric Biosciences director Frank Pasqualone received a grant of restricted stock. He was awarded 18,518 shares of common stock at no cash cost under the company’s 2020 Long-Term Incentive Plan. These shares will vest over time according to the plan and his award agreement.
After this equity grant, Pasqualone directly holds 26,423 shares of Enveric Biosciences common stock. This filing reflects a compensation-related stock award rather than an open-market purchase or sale.
WEBB MICHAEL D reported acquisition or exercise transactions in this Form 4 filing.
Enveric Biosciences director Michael D. Webb received a grant of 18,518 shares of restricted common stock. The award was made under the Enveric Biosciences, Inc. 2020 Long-Term Incentive Plan as amended, with vesting governed by the plan and his restricted stock agreement.
These shares were granted at no cash cost per share and are compensation rather than an open-market purchase. Following this grant, Webb directly holds a total of 26,416 shares of Enveric Biosciences common stock, subject to the vesting terms of the award.
Schabacker Marcus reported acquisition or exercise transactions in this Form 4 filing.
Enveric Biosciences director Marcus Schabacker received a grant of 18,518 shares of restricted common stock under the company’s 2020 Long-Term Incentive Plan. The grant was awarded at no cash cost to him and will vest according to the plan and his award agreement. After this grant, he directly holds 26,418 shares of Enveric common stock.
Kegler George A. reported acquisition or exercise transactions in this Form 4 filing.
Enveric Biosciences director George A. Kegler received a grant of 18,518 shares of restricted common stock on June 1, 2026 under the Enveric Biosciences, Inc. 2020 Long-Term Incentive Plan, as amended. The grant was awarded at $0.0000 per share as equity compensation.
After this award, Kegler directly holds 26,418 shares of Enveric Biosciences common stock. The restricted shares will vest over time in line with the terms of the 2020 Long-Term Incentive Plan and his restricted stock award agreement.
DeWitt Sheila reported acquisition or exercise transactions in this Form 4 filing.
Enveric Biosciences director Sheila DeWitt received a stock grant reported on Form 4. She was granted 18,518 shares of restricted common stock at no cash cost, issued under Enveric Biosciences, Inc. 2020 Long-Term Incentive Plan. After this award, she holds 26,306 common shares directly.
Enveric Biosciences, Inc. granted Chief Innovation Officer Peter J. Facchini 25,000 restricted stock units of common stock under its 2020 Long-Term Incentive Plan. Each unit will convert into one share of common stock as it vests, subject to continued employment.
One-fourth of the RSUs vest after one year, with an additional one-thirty-sixth vesting monthly until any remaining units vest on the fourth anniversary of grant. Following this award, Facchini holds 27,755 shares of common stock, adjusted for a prior 12-for-1 reverse stock split effective October 28, 2025.